Bayer : combines pharmaceutical research and development unit

Leverkusen, November 30, 2017 - Following the formation of a dedicated strategic business unit oncology earlier this year within its pharmaceuticals division, Bayer announced today to further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership. This unit will combine all research and development activities for therapeutic areas cardiology, gynecology, ophthalmology, hematology as well as oncology research within the company's pharmaceuticals division.

Joerg Moeller, 53, currently Head of Development at Bayer's pharmaceuticals division will become Head of Research and Development effective January 1, 2018. Andreas Busch, currently Head of Drug Discovery within the pharmaceuticals division of Bayer has decided to pursue a new career opportunity at another company.

'The combined organization will enable us to seamlessly steer all the important activities of Research and Development, with a single objective to further enhance the delivery of much needed new treatment options to patients,' said Dieter Weinand, President of Bayer's Pharmaceuticals Division and Member of the Board of Management of Bayer AG. 'Joerg has an exceptional track record of bringing new medicines to patients, which have the potential to increase their quality of life and address serious medical conditions, and I trust that our team will be even more successful in doing so together under his leadership. At the same time we thank Andreas Busch for all his valuable contributions to our company and wish him much success in his future endeavors.'

Joerg Moeller has been Head of Development at the company's pharmaceuticals division since February 1, 2014.

Joerg Moeller's career at Bayer AG began in 1993 in the Clinical Research International department, where he worked as a clinical project manager at the Pharmaceutical Research Center in Wuppertal. This was followed by a variety of managerial positions with increasing responsibility in Clinical Development in the United States and Canada. In 2001, Moeller returned to Germany and was appointed Vice President of Strategic Drug Development Cardiovascular. From 2002 to 2003, he was in charge of the Global Clinical Strategy department of former Bayer HealthCare's Pharmaceuticals Division.

He was then appointed Head of Global Clinical Development, in which capacity he was based in the United States.

In his new role Joerg Moeller will continue to report to Dieter Weinand and be a member of the company's Pharmaceutical Executive Committee.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 99,600 people and had sales of EUR 34.9 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For more information, go towww.bayer.com.

Follow us on Facebook:http://www.facebook.com/pharma.bayer
Follow us on Twitter:https://twitter.com/BayerPharma
Find more information atwww.pharma.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website atwww.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.